Home
overview

ADMET studies perform a vital role in the drug discovery process. Early stage In-Silico models can predict the viability of a new novel drug before anyone steps into a lab. The In-Vitro and In-Vivo models allow the testing of new molecules to discover how tell they cope in a physiological environment and save Pharma companies millions by stopping the development of drugs destined to fail. As more data is generated by the lab studies, more data becomes available for the computational scientists and so our predictive abilities improve.

This conference will address the barriers that are currently faced by the PK/PD community and also how recent discoveries have improved the understanding of the mechanisms involved in ADME-Tox. It will also address the new technologies and techniques being developed to overcome the classic physiological barriers to drug bioavailability.
 

Attendees will hear presentations from senior experts in the field on the current issues as well as case studies from recent drug development programmes.

ADMET studies are one of the most important parts of the pharmaceutical industry, and ADME and predictive toxicology studies are paramount in the discovery and development of new pharmaceutical drugs. The SMi group are proud to present this fantastic opportunity to learn about the latest developments in the industry, and hear from top members of the field from companies such as Merck Serono, Lundbeck Ltd., Pfizer, Abbott and Bayer.

  • Hear updates on the latest In-Vitro, In-Vivo and In-Silico methods and how combinations of these approaches can be used to minimize the risk of adverse drug reactions
  • Discuss new technologies for Small & Large molecule projects in drug discovery to enhance R&D productivity
  • Learn and discuss how recent developments in the understanding of drug transporters and Modelling&simulation approaches continue to impact how we should translate those data/knowledge in drug design and in predicting drug interaction
  • Hear about tecniques for optimisation of predictive studies
  • Explore the challanges faced in producing biologic drugs with high bioavailability and the best techniques to overcome these issues

Industry Profile:

Chief Executives, Vice Presidents, Heads, Directors, Chief Scientists and Project Leaders in:

  • ADME-Tox
  • DMPK
  • PK/PD
  • Metabolomics
  • Formulation
  • Nanotechnology
  • Toxicology
  • Biologic Developent
  • Computational Chemistry
  • Hepatic metabolism
  • Genotoxicity
  • Translational Science
  •  

Previous Companies in Attendance:

Abbott Laboratories; Alex Alexander Consulting; AstraZeneca; Blizard Institute of Cell & Molecular Science; Boehringer Ingelheim Pharma GmbH & Co. KG; BTG; Cancer Research Technology; Cancer Research UK; Cellectis Bioresearch; CXR Biosciences; Cyprotex Plc; Cyprotex Services Limited; Dr Margareta Fischer-Bosch Institute Of Clinical Phamacology; Eli Lilly; Eli Lilly & Co; Eli Lilly & Co. Ltd; European Collection Of Cell Cultures; FMC Corporation; Genetech; Gent University; Gentronix; GlaxoSmithKline; Heptares Therapeutics; Hungarian Academy of Sciences; Imperial College; Imperial College London West London Renal and Transplant Centre Hammersmith Hospital; King's College London; Leo Pharma; Lexicon Pharmaceuticals Inc; Lilly; London Technology Network; MSD; Muscagen Ltd; Novartis International AG; Pfizer; Polyphor Ltd; Sirius Analytical Instruments; Sovicell; The University of Buckingham; UCB; UCL Cancer Institute; Vertex; Vrije Universiteit Brussel and XenoTech

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Hugues Dolgos

Hugues Dolgos, Head, Global DMPK, Merck Serono S.A.

9:10 How can DMPK contribute to enhance the R&D Productivity?

Hugues Dolgos

Hugues Dolgos, Head, Global DMPK, Merck Serono S.A.

  • What can we learn from the past?
  • What is the current & future role of DMPK in R&D?
  • Focus area in drug discovery: Generation of therapeutic hypothesis.
  • Focus area in drug development: Quantitative drug drug interaction; Drug induced liver injury
  • 9:50 Outsourcing strategies: A view from both side of the fence

    Richard Weaver

    Richard Weaver, Director, Xenogesis

  • Landscape setting. Why the need?
  • What is being out-sourced? Capacity or Creativity?
  • Can outsourcing fix the problem of rising R&D costs and reduce the high risk nature of R&D?
  • Opportunities for strategic alliances
  • The future model of R&D
  • 10:30 Morning Coffee

    11:00 ADME for biologics the progress and challenges

    David Fairman

    David Fairman, Senior Clinical Pharmacokinetist, MedImmune Ltd

  • Differences between small molecules and biologics
  • Complexities in modelling biologic PK and PKPD
  • Half life modification for antibody therapeutics
  • 11:40 Case Study: Creating a novel high content screening assay to predict human hepatotoxicity

    Mikael Persson

    Mikael Persson, Exploratory Toxicology, Lundbeck Limited

  • Using multi-parametric analysis and data generated models for prediction of human drug-induced liver injury
  • Validation of the assay: sensitivity and selectivity using marketed drugs with known hepatotoxicity profile
  • Practical implementation in drug discovery: compound prioritization, similarity clustering with known compounds, and guidance on safe dosages
  • 12:20 Networking Lunch

    13:50 Metabolic stability assays: Correcting for microsomal binding using solid supported liver membrane vasicles (TRANSIL)

    Hinnerk Boriss

    Hinnerk Boriss, CEO, Sovicell

  • Rapid assay with only 12 minutes incubation time
  • Universally applicable assay through direct measurement of membrane-water distribution coefficient
  • Highly cost effective due to minimal labour requirement and multiplexing
  • 14:30 Computational approaches to ADMET

    Kiyoyuki Omoto

    Kiyoyuki Omoto, Computational Scientist, Pfizer

  • ADMET statistical modelling
  • Protein modelling of GPCR + ion channel targets
  • Pharmacophore modelling and docking simulation
  • 2D/3D virtual screening
  • 15:10 Afternoon Tea

    15:40 Predicting hERG liabilities using different In-Silico methods

    Luca Settimo

    Luca Settimo, Researcher Scientist, Vertex

  • hERG liabilities in pharmaceutical research
  • Role of pKa in hERG toxicity
  • QSAR vs machine learning methodologies in predicting hERG
  • 16:20 Attrition in drug discovery: How can computational approaches help?

    Alexander Alex

    Alexander Alex, Independent Consultant, Alexander Alex Consultancy

  • Productivity and reasons for attrition in the pharmaceutical industry
  • Computational models for predicting human absorption
  • Prediction of drug metabolism using computational approaches
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Richard Weaver

    Richard Weaver, Director, Xenogesis

    9:10 Interplay between CYP3A and Drug Transporters

    Robert van Waterschoot

    Robert van Waterschoot, Laboratory Head DMPK, Abbott Laboratories Company

  • Pharmacokinetic and toxicological consequences of the interplay between CYP3A and drug transporters
  • Improving the oral bioavailability by dual CYP3A and P-glycoprotein inhibition
  • Studies with CYP3A/drug transporter knockout mice: opportunities and pitfalls
  • 9:50 Drug transporters in development of GLPG0634 a selective JAK1 inhibitor for the treatment of rheumatoid arthritis

    Florence Namour

    Florence Namour, Senior DMPK Manager, Galapagos

     

  • Short introduction on RA and GLPG0634
  • Approach for drug transporters investigation in GLPG0634 development
  • 10:30 Morning Coffee

    11:00 Through the looking-glass': Practical solutions for enhanced insight into transporter interactions

    Sid Bhoopathy

    Sid Bhoopathy, Chief Operating Officer, Absorption Systems

  • Illustration and rationalization of inheren conflicts in results from multiplue in-vitro test systems
  • Improved assay outcomes based on recognition of the interplay between transporter test-system and test compund cheracteristics
  • Use of a design-augmented approach to fulfil regulatory expectations abd maximise clinical translatability
  • 11:40 Investigation of in vivo functions of OATPs

    Evita Van De Steeg

    Evita Van De Steeg, Researcher, TNO Quality of Life

     

  • Recent insights from OATP knockout and humanized transgenic mouse models
  • Role of OATP transporters in drug pharmacokinetics
  • Unexpected roles of OATPs in bilirubin handling and their interaction with efflux transporters
  •  

    12:20 Networking Lunch

    13:50 Developing better models for efflux and drug-transporter interaction

  • The ITC recommendations in practical application
  • Failings of the current models for efflux and what needs to be improved?
  • Recommendations for designing and implementing transporter studies in the future
  • Richard Weaver

    Richard Weaver, Director, Xenogesis

    Sid Bhoopathy

    Sid Bhoopathy, Chief Operating Officer, Absorption Systems

    Laurent Salphati

    Laurent Salphati, Senior Scientist, Genentech

    Andreas Reichel

    Andreas Reichel, Head of Research PK, Bayer

    14:30 Optimizing compounds for brain penetration - Discovery of a brain-penetrant oncology compound

    Laurent Salphati

    Laurent Salphati, Senior Scientist, Genentech

  • In silico and in vitro assessment of relevant properties
  • Measurements and prediction of brain concentrations - Is CSF relevant?
  • Brain distribution - Example with Kinase inhibitor
  • 15:10 Afternoon Tea

    15:40 Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept

    Andreas Reichel

    Andreas Reichel, Head of Research PK, Bayer

  • The role of the blood-brain barrier in CNS drug discovery
  • Current experimental methods to brain penetration and their pitfalls
  • Rate and extend as key aspects to describe drug distribution within the CNS
  • Optimisation parameters to improve the free drug exposure in the brain
  • An integrated approach to assess brain penetration and to link it with efficacy
  • 16:20 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alexander Alex

    Alexander Alex

    Independent Consultant, Alexander Alex Consultancy
    Hugues Dolgos

    Hugues Dolgos

    Head, Global DMPK, Merck Serono S.A.

    Alexander Alex

    Independent Consultant, Alexander Alex Consultancy
    Alexander Alex

    Andreas Reichel

    Head of Research PK, Bayer
    Andreas Reichel

    David Fairman

    Senior Clinical Pharmacokinetist, MedImmune Ltd
    David Fairman

    Evita Van De Steeg

    Researcher, TNO Quality of Life
    Evita Van De Steeg

    Florence Namour

    Senior DMPK Manager, Galapagos
    Florence Namour

    Hinnerk Boriss

    CEO, Sovicell
    Hinnerk Boriss

    Hugues Dolgos

    Head, Global DMPK, Merck Serono S.A.
    Hugues Dolgos

    Kiyoyuki Omoto

    Computational Scientist, Pfizer
    Kiyoyuki Omoto

    Laurent Salphati

    Senior Scientist, Genentech
    Laurent Salphati

    Luca Settimo

    Researcher Scientist, Vertex
    Luca Settimo

    Mikael Persson

    Exploratory Toxicology, Lundbeck Limited
    Mikael Persson

    Richard Weaver

    Director, Xenogesis
    Richard Weaver

    Robert van Waterschoot

    Laboratory Head DMPK, Abbott Laboratories Company
    Robert van Waterschoot

    Sid Bhoopathy

    Chief Operating Officer, Absorption Systems
    Sid Bhoopathy

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.